2017 Speakers

In 2017, over 190 industry defining speakers lead the discussion at World Oprhan Drug Conggress USA 2017. Reserve your speaking spot now for 2018!

 

Christopher Adams, Chief Executive Officer, Andarix Pharmaceuticals

Christopher Adams at World Orphan Drug Congress USA 2017

Chris Adams, CEO, Andarix Pharmaceuticals

Chris Adams at World Orphan Drug Congress USA 2017

Sudhir Agrawal, President of Research, Idera Pharmaceuticals, Inc.

Sudhir Agrawal at World Orphan Drug Congress USA 2017

Steven Anderson, Chief Scientific Officer, Covance

Steven Anderson at World Orphan Drug Congress USA 2017

Einar Andreassen, Senior Adviser, Norwegian Medicines Agency

Einar Andreassen at World Orphan Drug Congress USA 2017

Irene Aquino, Senior Director, Patient Advocacy and Engagement, Alnylam Pharmaceuticals

Irene Aquino at World Orphan Drug Congress USA 2017

Diego Ardigo, Project Leader for Advanced Therapies, CHIESI Farmaceutici Spa

Diego Ardigo at World Orphan Drug Congress USA 2017

Donna Armentano, Global Head of Gene Therapy, Pfizer

Donna Armentano at World Orphan Drug Congress USA 2017

Heather Ascani, Business Operations, Applied Systems Biology Core Internal Medicine – Nephrology, University of Michigan

Heather Ascani at World Orphan Drug Congress USA 2017

Alison Bateman House, Assistant Professor, Division of Medical Ethics, New York University Langone Medical Center

Alison Bateman House at World Orphan Drug Congress USA 2017

Michelle Berg, Vice President, Patient Advocacy, Abeona Therapeutics Inc.

Michelle Berg at World Orphan Drug Congress USA 2017

Diana Bharucha, Assistant Professor of Neurology, Children’s National Health System

Diana Bharucha at World Orphan Drug Congress USA 2017

Sonal Bhatia, Vice President, North America Medical Lead, Pfizer Rare Disease

Sonal Bhatia at World Orphan Drug Congress USA 2017

Stella Blackburn, VP, Global Head of Risk Management, QuintilesIMS

Stella Blackburn at World Orphan Drug Congress USA 2017

Dale Bodian, Manager Bioinformatics Scientist, Inova Translational Medicine Institute

Dale Bodian at World Orphan Drug Congress USA 2017

Nadia Bodkin, Founder, EDSers United & Community Engagement Team Leader, rareLife solutions

Nadia Bodkin at World Orphan Drug Congress USA 2017

John Boland, VP pro dev, Atlantic Research Group Inc

John Boland at World Orphan Drug Congress USA 2017

Jill Bonjean, Corporate and Foundation Relations Director, EURORDIS

Jill Bonjean at World Orphan Drug Congress USA 2017

Katrine Bosley, Chief Executive Officer, Editas Medicine

Katrine Bosley at World Orphan Drug Congress USA 2017

Katherine Brandt, Manager, Marketing and Sales Operations, Afton Scientific Llc

Katherine Brandt at World Orphan Drug Congress USA 2017

Ari Brettman, Principal, Clarus Ventures

Ari Brettman at World Orphan Drug Congress USA 2017

Murray Brilliant, Senior Research Scientist and Center Director, Marshfield Clinic Research Foundation

Murray Brilliant at World Orphan Drug Congress USA 2017

Max Bronstein, Chief Advocacy & Science Policy Officer, EveryLife Foundation for Rare Diseases

Max Bronstein at World Orphan Drug Congress USA 2017

Philip J. Brooks, Program Director, Office of Rare Diseases Research, NCATS, NIH

Philip J. Brooks at World Orphan Drug Congress USA 2017

Anna Bucsics, External Lecturer, MoCA board member, University of Vienna

Anna Bucsics at World Orphan Drug Congress USA 2017

Shawn Burgess, Senior Investigator, Translational and Functional Genomics Branch, Head, Developmental Genomics Sect, NHGRI, NIH

Shawn Burgess at World Orphan Drug Congress USA 2017

Molly Burich, Associate Director of Public Policy, Biosimilars, Pipeline and Reimbursement, Boehringer Ingelheim

Molly Burich at World Orphan Drug Congress USA 2017

Andrea Califano, Chair, Systems Biology Department, Columbia University U.S.A.

Andrea Califano at World Orphan Drug Congress USA 2017

Carlos Camozzi, Group Chief Medical Officer, Simbec-Orion

Carlos Camozzi at World Orphan Drug Congress USA 2017

Jeff Ceitlin, Chief Commercial Officer, HVH Patient Precision Analytics

Jeff Ceitlin at World Orphan Drug Congress USA 2017

Fabrice Chartier, Chief Operating Officer, Simbec-Orion

Fabrice Chartier at World Orphan Drug Congress USA 2017

Angela Chaves, President, Federacion Colombiana de Enfermedades Raras

Angela Chaves at World Orphan Drug Congress USA 2017

William W. Chin, CMO, Executive VP, Science and Regulatory Affairs, PhRMA

William W. Chin at World Orphan Drug Congress USA 2017

Leah Christl, AD,Therapeutic Biologics & Biosimilars, F.D.A.

Leah Christl at World Orphan Drug Congress USA 2017

Margaret Collins, Professor of Pediatrics, Cincinnati Childrens Hospital

Margaret Collins at World Orphan Drug Congress USA 2017

Francesca Cook, Director, Pricing and Market Access, RegenxBio

Francesca Cook at World Orphan Drug Congress USA 2017

Jodi Cook, Chief Operating Officer, Agilis Biotherapeutics

Jodi Cook at World Orphan Drug Congress USA 2017

John Coster, Director, Division of Pharmacy, Center for Medicare and Medicaid Services

John Coster at World Orphan Drug Congress USA 2017

John F. Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics

John F. Crowley at World Orphan Drug Congress USA 2017

Gregory Daniel, Deputy Director, Duke University

Gregory Daniel at World Orphan Drug Congress USA 2017

Rajiv Datar, Co Founder and Chief Executive Officer, D.N.X. Biopharmaceuticals Inc

Rajiv Datar at World Orphan Drug Congress USA 2017

Jefferson Davis, Chief Business Officer, Acer Therapeutics

Jefferson Davis at World Orphan Drug Congress USA 2017

Ronald DeBellis, Chief Scientific Officer, National Organization for Rare Disorders

Ronald DeBellis at World Orphan Drug Congress USA 2017

Peter Dehnel, Medical Director, Blue Cross and Blue Shield of Minnesota

Peter Dehnel at World Orphan Drug Congress USA 2017

Keith DeMatteo, Director, Global Procurement, Bristol Myers Squibb

Keith DeMatteo at World Orphan Drug Congress USA 2017

Daniel Donovan, Co-Founder and CEO, rareLife solutions

Daniel Donovan at World Orphan Drug Congress USA 2017

Kelly Du Plessis, Chief Executive Officer, Rare Diseases South Africa

Kelly Du Plessis at World Orphan Drug Congress USA 2017

Paul Eccles, PhD, Client Services Director, Cello Health Insight

Paul Eccles, PhD at World Orphan Drug Congress USA 2017

Glyn Edwards, Chief Executive Officer, Summit Therapeutics

Glyn Edwards at World Orphan Drug Congress USA 2017

Florian Eichler, Associate Professor of Neurology, Massachusetts General Hospital

Florian Eichler at World Orphan Drug Congress USA 2017

David Elvira Martinez, Director, CatSalut, Catalunya Health Service

David Elvira Martinez at World Orphan Drug Congress USA 2017

Neal Farber, Chief Executive Officer, NeuroHealing Pharmaceuticals

Neal Farber at World Orphan Drug Congress USA 2017

Wildon Farwell, Senior Medical Director, Clinical Development, Biogen

Wildon Farwell at World Orphan Drug Congress USA 2017

Brian Flatley, Business Development Director, S3 Connected Health

Brian Flatley at World Orphan Drug Congress USA 2017

Mary Frances Harmon, Head of Global Patient Advocacy, PTC Therapeutics

Mary Frances Harmon at World Orphan Drug Congress USA 2017

Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

Pat Furlong at World Orphan Drug Congress USA 2017

William Gahl, Clinical Director, Director of the N.I.H. Undiagnosed Diseases Program

William Gahl at World Orphan Drug Congress USA 2017

Vignesh Ganapathy, AD of Advocacy & Government Relations, EveryLife Foundation for Rare Diseases

Vignesh Ganapathy at World Orphan Drug Congress USA 2017

Chris Garabedian, Chairman, Xontogeny LLC

Chris Garabedian at World Orphan Drug Congress USA 2017

Eric Gascho, Vice President of Government Affairs, National Health Council

Eric Gascho at World Orphan Drug Congress USA 2017

Pamela Gavin, Chief Operating Officer, National Organization for Rare Disorders

Pamela Gavin at World Orphan Drug Congress USA 2017

Jayne Gershkowitz, Chief Patient Advocate, Amicus Therapeutics Inc

Jayne Gershkowitz at World Orphan Drug Congress USA 2017

Dr Christopher Gibson, Chief Executive Officer, Recursion Pharmaceuticals

Dr Christopher Gibson at World Orphan Drug Congress USA 2017

Michael Goettler, Global President, Pfizer Rare Disease

Michael Goettler at World Orphan Drug Congress USA 2017

Jonathan Goldsmith, Associate Director Rare Diseases Program, Food And Drug Administration

Jonathan Goldsmith at World Orphan Drug Congress USA 2017

Rashmi Gopal-Srivastava, Dir, Extramural Research Program, Office Rare Diseases, National Institutes of Health

Rashmi Gopal-Srivastava at World Orphan Drug Congress USA 2017

Hazel Gorham, Senior Director of Biosimilars Development, PRA Health Sciences

Hazel Gorham at World Orphan Drug Congress USA 2017

Scott Gray, Chief Executive Officer, Clincierge

Scott Gray at World Orphan Drug Congress USA 2017

James Greenwood, Chief Executive Officer, Biotechnology Industry Organization

James Greenwood at World Orphan Drug Congress USA 2017

Stephen Groft, Senior Advisor to the Director, NCATS, N.I.H

Stephen Groft at World Orphan Drug Congress USA 2017

Yi Han, Executive Vice President of Market Access and HEOR, Cello Health Market Access

Yi Han at World Orphan Drug Congress USA 2017

Colin Hayward, Chief Medical Officer, Premier Research

Colin Hayward at World Orphan Drug Congress USA 2017

Gudrun Helga Haroardottir, Director, Einstok Born Support Group For Children With Rare Disorders

Gudrun Helga Haroardottir at World Orphan Drug Congress USA 2017

Johan Heylen, Chief Commercial Officer, Ablynx

Johan Heylen at World Orphan Drug Congress USA 2017

Kenneth Hobby, President, Cure SMA

Kenneth Hobby at World Orphan Drug Congress USA 2017

Angus Hogg, Vice President Hunters (MPSII) Franchise, Shire Pharmaceuticals Ltd

Angus Hogg at World Orphan Drug Congress USA 2017

Kay holcombe, Senior Vice President for Science Policy, Biotechnology Industry Organization (BIO)

Kay holcombe at World Orphan Drug Congress USA 2017

Tony Howell, Co-Founder & COO, rareLife solutions

Tony Howell at World Orphan Drug Congress USA 2017

Kate Hudson Farmer, Director, Front-End Innovation, Drug Delivery, Medicom Innovation Partner a/s

Kate Hudson Farmer at World Orphan Drug Congress USA 2017

Wills Hughes-Wilson, Senior Vice President, Chief Patient Access Officer, Sobi

Wills Hughes-Wilson at World Orphan Drug Congress USA 2017

Michelle Hylan, CEO, Innov8tive Research Consulting, Consultant, Innov8tive Research Consulting

Michelle Hylan at World Orphan Drug Congress USA 2017

Reina Improgo, Senior Research Scientist, Idera Pharmaceuticals, Inc.

Reina Improgo at World Orphan Drug Congress USA 2017

Raul Insa, Founder and Chief Executive Officer, SOM Biotech SL

Raul Insa at World Orphan Drug Congress USA 2017

Dr Cynthia Jackson, VP & Head, Pediatric & Rare Disease Cnrts of Excellence, QuintilesIMS

Dr Cynthia Jackson at World Orphan Drug Congress USA 2017

Edmund Jessop, Medical Adviser, National Health Service

Edmund Jessop at World Orphan Drug Congress USA 2017

Mehul Jhaveri, Director, Medical Value Based Outcomes, Biogen

Mehul Jhaveri at World Orphan Drug Congress USA 2017

Ashley Kamil, Vice President, Digital Services, ClinicalMind

Ashley Kamil at World Orphan Drug Congress USA 2017

Matt Kapusta, Chief Executive Officer, uniQure

Matt Kapusta at World Orphan Drug Congress USA 2017

Derek Kelaita, VP, Business Development, ArmaGen Technologies

Derek Kelaita at World Orphan Drug Congress USA 2017

Jas Khera, Managing Director EU, WEP Clinical

Jas Khera at World Orphan Drug Congress USA 2017

Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

Sven Kili at World Orphan Drug Congress USA 2017

Takashi K Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc

Takashi K Kishimoto at World Orphan Drug Congress USA 2017

Diane Kleinermans, Advisor to the Ministry of Health and Social Affairs Belgium, Belgian Federal Government

Diane Kleinermans at World Orphan Drug Congress USA 2017

Ragnar Klingberg, CEO, EmeraMed

Ragnar Klingberg at World Orphan Drug Congress USA 2017

Christopher Komelasky, Senior Director, Site and Patient Access, PPD

Christopher Komelasky at World Orphan Drug Congress USA 2017

Walter Kowtoniuk, Director, Strategy and Operations, Fulcrum Therapeutics

Walter Kowtoniuk at World Orphan Drug Congress USA 2017

Matthias Kretzler, Professor of Internal Medicine, Computational Medicine and Bioinformatics, University of Michigan

Matthias Kretzler at World Orphan Drug Congress USA 2017

Karen Krumeich, Senior Vice President & Chief Financial Officer, Soligenix

Karen Krumeich at World Orphan Drug Congress USA 2017

Niels Kure, Director, Front-End Innovation, Drug Delivery, Medicom Innovation Partner a/s

Niels Kure at World Orphan Drug Congress USA 2017

Jennifer Kwon, Associate Professor of Neurology and Pediatrics, University of Rochester

Jennifer Kwon at World Orphan Drug Congress USA 2017

David Lapidus, President, Lapidus Data

David Lapidus at World Orphan Drug Congress USA 2017

David Larwood, CEO and Founder, Valley Fever Solutions

David Larwood at World Orphan Drug Congress USA 2017

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam at World Orphan Drug Congress USA 2017

Nadea Leavitt, Engagement Mgr, Predictive Analytics, RW Insights, QuintilesIMS

Nadea Leavitt at World Orphan Drug Congress USA 2017

John Leonard, Executive Vice President, R&D, Intellia Therapeutics Inc

John Leonard at World Orphan Drug Congress USA 2017

Nick Leschly, President and Chief Executive Officer, bluebird bio

Nick Leschly at World Orphan Drug Congress USA 2017

Aneta Lipińska, Head of Analysis and Strategy Division, President's Office, Agency for Health Technology Assessment and Tariff System

Aneta Lipińska at World Orphan Drug Congress USA 2017

David Litwack, Personalized Medicine Staff, U.S. Food And Drug Administration

David Litwack at World Orphan Drug Congress USA 2017

Aoife M Brennan, Chief Medical Officer, Synlogic Therapeutics

Aoife M Brennan at World Orphan Drug Congress USA 2017

Jack M. Mycka, Chief Executive Officer, Medical Marketing Economics

Jack M. Mycka at World Orphan Drug Congress USA 2017

Alastair Macdonald, Exec Director, RWLP Strategy, Global, INC Research

Alastair Macdonald at World Orphan Drug Congress USA 2017

Stephen Marcus, Chief Executive Officer, Cantex Pharmaceuticals

Stephen Marcus at World Orphan Drug Congress USA 2017

Jeffrey D. Marrazzo, Co Founder and Chief Executive Officer, Spark Therapeutics

Jeffrey D. Marrazzo at World Orphan Drug Congress USA 2017

Marc Martinell, Chief Executive Officer, Minoryx Therapeutics

Marc Martinell at World Orphan Drug Congress USA 2017

John Maslowski, CEO, Fibrocell

John Maslowski at World Orphan Drug Congress USA 2017

Gary Mathias, Chief Executive Officer, Thetis Pharmaceuticals Llc

Gary Mathias at World Orphan Drug Congress USA 2017

Howard Mayer, SVP & Head of Global Clinical Development, Shire Pharmaceuticals

Howard Mayer at World Orphan Drug Congress USA 2017

James McDermott, Vice President, Cello Health BioConsulting

James McDermott at World Orphan Drug Congress USA 2017

John McKew, Chief Scientific Officer, Lumos Pharma

John McKew at World Orphan Drug Congress USA 2017

Paul Melmeyer, Associate Director of Public Policy, National Organization for Rare Disorders

Paul Melmeyer at World Orphan Drug Congress USA 2017

Jerry R. Mendell, Director, Center for Gene Therapy, Nationwide Children's Hospital

Jerry R. Mendell at World Orphan Drug Congress USA 2017

Debra Miller, CEO, CureDuchenne

Debra Miller at World Orphan Drug Congress USA 2017

Christopher Missling, President and Chief Executive Officer, Anavex Life Sciences

Christopher Missling at World Orphan Drug Congress USA 2017

Juliet Moritz, Executive Director, Strategic Development, Rare Diseases, Premier Research

Juliet Moritz at World Orphan Drug Congress USA 2017

Richard Moscicki, Deputy Director for Science Operations, CDER, FDA

Richard Moscicki at World Orphan Drug Congress USA 2017

Joseph Musumeci, Senior Advisor, BluePrint Orphan

Joseph Musumeci at World Orphan Drug Congress USA 2017

Jeff Myers, CEO, Medicaid Health Plans of America

Jeff Myers at World Orphan Drug Congress USA 2017

Francois Nader, Former President & CEO, NPS, Board Chairman, Acceleron Pharma

Francois Nader at World Orphan Drug Congress USA 2017

Nikhil Nair, Assist Professor, Dept of Chemical and Biological Engineering, Tufts University

Nikhil Nair at World Orphan Drug Congress USA 2017

Yukiko Nishimura, President, NPO, Japan Patients Association, ASrid

Yukiko Nishimura at World Orphan Drug Congress USA 2017

David Norris, Rare Disease Patient Affairs Team Leader, Pfizer

David Norris at World Orphan Drug Congress USA 2017

Sean O'Bryan, Vice President, Regulatory Affairs & Quality Assurance, Lysogene

Sean O'Bryan at World Orphan Drug Congress USA 2017

Letitia O'Dwyer, Chief Executive Officer, New Zealand Organisation For Rare Disorders

Letitia O'Dwyer at World Orphan Drug Congress USA 2017

Romina Ortiz, VP Policy & Patient Advocacy, Rare Genomics Institute

Romina Ortiz at World Orphan Drug Congress USA 2017

Luca Pani, Former Gen Director AIFA, CHMP and SAWP Member, European Medicines Agency

Luca Pani at World Orphan Drug Congress USA 2017

Anne Pariser, Deputy Director, Office of Rare Diseases Research, NCATS, NIH

Anne Pariser at World Orphan Drug Congress USA 2017

Detlev Parow, Head of Department of Medicines, Therapeutic Appliances and Remedies, D.A.K.

Detlev Parow at World Orphan Drug Congress USA 2017

Nancy Parsons, VP Commercial Operations, Pharma Products, Leadiant Biosciences

Nancy Parsons at World Orphan Drug Congress USA 2017

Douglas Paul, Vice President and Partner, Medical Marketing Economics

Douglas Paul at World Orphan Drug Congress USA 2017

Eric Pauwels, SVP & General Manager, Americas, PTC Therapeutics

Eric Pauwels at World Orphan Drug Congress USA 2017

Edmund Pezalla, Fomer VP Pharmaceutical Policy and Strategy, Aetna

Edmund Pezalla at World Orphan Drug Congress USA 2017

Andreas Pleil, Sr Dr, Team Lead, Outcomes & Evidence Hematology, Pfizer

Andreas Pleil at World Orphan Drug Congress USA 2017

Horacio Plotkin, VP, Global Therapeutic Head, Pediatrics & Rare Diseases, PPD

Horacio Plotkin at World Orphan Drug Congress USA 2017

Sy Pretorius, SVP and Chief Scientific Officer, PAREXEL International

Sy Pretorius at World Orphan Drug Congress USA 2017

Harsha Rajasimha, Co Founder, Organization for Rare Diseases India

Harsha Rajasimha at World Orphan Drug Congress USA 2017

Gayatri Rao JD., MD,, Director, Orphan Products Development, FDA

Gayatri Rao JD., MD, at World Orphan Drug Congress USA 2017

Kate Rawson, Contributing Editor, Prevision Policy

Kate Rawson at World Orphan Drug Congress USA 2017

Francis Reed, Director, The Children’s Fund for Glycogen Storage Disease Research

Francis Reed at World Orphan Drug Congress USA 2017

Adam Resnick, Director, Ctr for Data Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia

Adam Resnick at World Orphan Drug Congress USA 2017

Trevor Richter, Director, Common Drug Review and Optimal Use, CADTH

Trevor Richter at World Orphan Drug Congress USA 2017

Kerry Robinson, Business Development Director Americas, S3 Connected Health

Kerry Robinson at World Orphan Drug Congress USA 2017

Philip Ross, Managing Director, J.P. Morgan Healthcare Investment Banking

Philip Ross at World Orphan Drug Congress USA 2017

Mark Rothera, Chief Commercial Officer, PTC Therapeutics

Mark Rothera at World Orphan Drug Congress USA 2017

Leonide Saad, CEO, Alkeus Pharmaceuticals Inc

Leonide Saad at World Orphan Drug Congress USA 2017

Peter Saltonstall, CEO, National Organization For Rare Disorders

Peter Saltonstall at World Orphan Drug Congress USA 2017

Amber Salzman, President and Chief Executive Officer, Adverum Biotechnologies

Amber Salzman at World Orphan Drug Congress USA 2017

Amanda Samanek, Executive Director, Genetic and Rare Disease Network, Australia

Amanda Samanek at World Orphan Drug Congress USA 2017

Jillian Savarese, Group Account Supervisor, ClinicalMind

Jillian Savarese at World Orphan Drug Congress USA 2017

Scott Schliebner, Vice President, Scientific Affairs, Rare Diseases, PRA Health Sciences

Scott Schliebner at World Orphan Drug Congress USA 2017

Prof Matthias Schönermark, Chief Executive Officer, SKC Beratungsgesellschaft

Prof Matthias Schönermark at World Orphan Drug Congress USA 2017

Ana Maria Serrato Navas, Country Manager, Colombia, Aegerion Pharmaceuticals

Ana Maria Serrato Navas at World Orphan Drug Congress USA 2017

Samuel Seward, Site Chair, Department of Medicine, Mount Sinai Hospital

Samuel Seward at World Orphan Drug Congress USA 2017

Jim Shaffer, Chief Business Officer, Eiger Biopharmaceuticals

Jim Shaffer at World Orphan Drug Congress USA 2017

Alex Sherman, Director of Strategic Development and Systems, Massachusetts General Hospital Neurological Clinical Research Institute

Alex Sherman at World Orphan Drug Congress USA 2017

Amandip Sidhu, EAP Director, WEP Clinical

Amandip Sidhu at World Orphan Drug Congress USA 2017

Ross Silver, Principal, Sylva International

Ross Silver at World Orphan Drug Congress USA 2017

Sascha Sonnenberg, Dipl.-Oec., MBA, Vice President Global CTD Sales & Operations, Marken

Sascha Sonnenberg at World Orphan Drug Congress USA 2017

Mark Sorrentino, Vice President, Scientific Affairs - Pediatrics, PRA Health Sciences

Mark Sorrentino at World Orphan Drug Congress USA 2017

Barbara Sosnowski, VP of External R&D Innovation and Head of Cambridge Research Units, Pfizer

Barbara Sosnowski at World Orphan Drug Congress USA 2017

Kaye Spratt, VP, Regulatory, Abeona Therapeutics LLC

Kaye Spratt at World Orphan Drug Congress USA 2017

Jeremy Springhorn, Partner Corporate Development, Flagship Ventures

Jeremy Springhorn at World Orphan Drug Congress USA 2017

Stephen Squinto, Venture Partner, Orbimed

Stephen Squinto at World Orphan Drug Congress USA 2017

Makoto Suematsu, Founding President, Japan Agency for Medical Research and Development

Makoto Suematsu at World Orphan Drug Congress USA 2017

Mary Szela, Chief Executive Officer, Novelion Therapeutics

Mary Szela at World Orphan Drug Congress USA 2017

Keren Tenenbaum, Assistant General Counsel, Patient Health and Impact, Pfizer

Keren Tenenbaum at World Orphan Drug Congress USA 2017

Adeline Vanderver, Pediatric Neurologist, Children's Hospital of Philadelphia

Adeline Vanderver at World Orphan Drug Congress USA 2017

Katie Verb, Director, Policy & Government Relations, Hemophilia Federation of America

Katie Verb at World Orphan Drug Congress USA 2017

Birgitte Volck, Senior Vice President, Head of R&D Rare Diseases, GlaxoSmithKline

Birgitte Volck at World Orphan Drug Congress USA 2017

Timothy Walbert, Chairman, President, and Chief Executive Officer, Horizon Pharma plc

Timothy Walbert at World Orphan Drug Congress USA 2017

Julie Walters, Founder, Raremark

Julie Walters at World Orphan Drug Congress USA 2017

Susan Ward, Founder and Executive Director, The Collaborative Trajectory Analysis Project (cTAP)

Susan Ward at World Orphan Drug Congress USA 2017

Ilyas Washington, , Alkeus Pharmaceuticals Inc

Ilyas Washington at World Orphan Drug Congress USA 2017

Leslie Wetherell, Exec Director, Rare Disease, Worldwide Clinical Trials

Leslie Wetherell at World Orphan Drug Congress USA 2017

Diane White, Assoc. Dir Development Sciences, Biomarin

Diane White at World Orphan Drug Congress USA 2017

James Wilson, Director, Orphan Disease Center, University of Pennsylvania

James Wilson at World Orphan Drug Congress USA 2017

Barbara Wuebbels, Vice President of Patient Advocacy, Audentes Therapeutics

Barbara Wuebbels at World Orphan Drug Congress USA 2017

Michael Wyand, Former President and Chief Operating Officer, EPIRUS Biopharma

Michael Wyand at World Orphan Drug Congress USA 2017

Nora Yang, Director, Portfolio Management and Program Operations, NCATS, National Institutes of Health

Nora Yang at World Orphan Drug Congress USA 2017

Chen Yu, Managing Partner, Vivo Capital

Chen Yu at World Orphan Drug Congress USA 2017

Stay connected

Sign up for event updates